Cellectis is a clinical-stage biopharmaceutical company developing gene-edited allogeneic cell therapy products for oncology, leveraging proprietary genome editing and CAR T-cell immunotherapy technologies to advance therapeutic candidates through clinical evaluation. The company generates revenues primarily through collaboration agreements, licensing arrangements, and research tax credits, with its largest revenue source being a joint research and collaboration arrangement that provides reimbursement of research costs and milestone payments potentially reaching hundreds of millions of dollars per candidate. Operating with research and manufacturing facilities in the United States and France, Cellectis does not expect material product revenues unless it successfully completes development and obtains regulatory approval for its candidates, requiring substantial additional capital for clinical progression, manufacturing expansion, and commercialization infrastructure.